Vernalis and Servier sign three-year oncology agreement
UK firm Vernalis and Servier, France's largest privately owned pharmaceutical company, have signed a three-year joint oncology agreement, focused on the discovery of drugs for a new target.
UK firm Vernalis and Servier, France's largest privately owned pharmaceutical company, have signed a three-year joint oncology agreement, focused on the discovery of drugs for a new target.
Under the terms of the collaboration, which uses Vernalis" proprietary fragment and structure-based drug discovery platform on this undisclosed cancer target, Vernalis will receive milestone payments and royalties on sales, the terms of which are not disclosed. Vernalis and Servier already have an agreement to develop two promising oncology targets involved in protein-protein interactions.
Ian Garland, ceo of Vernalis, said: "This latest collaboration with Servier confirms our excellent working relationship and Servier's recognition of the quality of our fragment and structure-based drug discovery platform."
Emmanuel Canet, president of Servier r&d, added: "We are benefiting significantly from our existing relationship with Vernalis as part of our strategy to increase our efforts in the development of novel anti-cancer therapeutic approaches. This new collaboration will further expedite the discovery of innovative compounds with potential use in therapeutic indications with high unmet medical need."
Vernalis currently has seven product candidates in clinical development (two of which are partnered) and two programmes in pre-clinical trials (one with a partner) and other competitive research programmes.
Vernalis
T +44 118 977 3133